West Pharmaceutical Services, Inc. (WST)

Over the past six months, West Pharmaceutical Services, Inc. (WST) stock has experienced notable movements. As of September 26, 2025, the share price was $261.52, a 12.87% decline from September 30, 2024, when it was $300.16. In Q1 2025, the company announced better-than-expected revenue and non-GAAP profit, although the stock had dropped sharply earlier in the year. In Q2 2025, WST shares surged after the company delivered a robust beat on earnings and revenue, and significantly raised its full-year guidance, driven by growth in its High-Value Product (HVP) segment. Robert McMahon was appointed as the incoming Chief Financial Officer, effective August 4, succeeding Bernard Birkett. West participated in several investor conferences in September 2025.

The provided information does not explicitly detail specific demand seasonality for West Pharmaceutical Services, Inc.'s products and services. Demand is likely driven by broader trends in the pharmaceutical and healthcare industries, such as the prevalence of chronic diseases, advancements in biologics, cell and gene therapies, and the growing trend of outsourcing in drug development. The strong demand for GLP-1 elastomer products indicates that specific therapeutic areas can significantly influence demand. Demand could be influenced by drug development cycles, regulatory approvals, and the launch of new injectable therapies.

West Pharmaceutical Services, Inc. (WST) is a global leader in designing, manufacturing, and selling containment and delivery systems for injectable drugs and healthcare products. Founded in 1923 and headquartered in Exton, Pennsylvania, the company operates in the Medical Equipment, Medical Devices, and Pharmaceutical sectors, specifically in the Surgical & Medical Instruments & Apparatus industry. The company operates through two segments: Proprietary Products, which focuses on components and systems for injectable drug delivery, including stoppers, seals, syringe components, administration systems, and drug containment solutions, serving biologic, generic, and pharmaceutical drug companies; and Contract-Manufactured Products, which involves the design, manufacture, and automated assembly of complex devices used in surgical, diagnostic, ophthalmic, injectable, drug delivery systems, and consumer products, serving pharmaceutical, diagnostic, and medical device companies.

West Pharmaceutical Services, Inc. has a significant global presence, operating in over 50 locations worldwide, including 25 manufacturing facilities. The company distributes its products and services directly and through a network of distributors across the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Approximately 55% of its revenue is generated from international markets, with 45% from the United States. Revenue distribution includes the United States (42%), Germany (13.8%), Ireland (9.7%), France (9.6%), other parts of Europe (13.1%), and other regions (11.8%).

While specific events directly impacting West Pharmaceutical Services' brand reputation in the past year are not extensively detailed, the company's strong financial performance and strategic initiatives suggest a generally positive standing within the industry. The surge in stock price following strong Q2 2025 earnings indicates positive market perception. Continuous innovation in injectable drug administration solutions and its role as a trusted partner contribute to its reputation. The opening of a new analytical laboratory in Germany and the launch of new products also reflect ongoing commitment to quality and advancement.

The ownership structure of West Pharmaceutical Services (WST) stock is primarily institutional, with approximately 74.4% to 80.65% held by institutional investors such as Vanguard Group Inc., BlackRock, Inc., and State Street Corp. Individual investors and public companies hold the remaining shares, with insiders owning approximately 0.57%.